Research analysts at Deutsche Bank started coverage on shares of Medidata Solutions (NASDAQ:MDSO) in a report issued on Friday, MarketBeat reports. The brokerage set a “buy” rating and a $78.00 price target on the stock. Deutsche Bank’s price objective points to a potential upside of 17.77% from the company’s current price.

MDSO has been the topic of a number of other reports. KeyCorp restated a “buy” rating and set a $86.00 target price on shares of Medidata Solutions in a research report on Sunday, September 17th. Royal Bank Of Canada started coverage on shares of Medidata Solutions in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $82.00 target price on the stock. Zacks Investment Research upgraded shares of Medidata Solutions from a “sell” rating to a “hold” rating in a research report on Wednesday, September 20th. SunTrust Banks restated a “buy” rating and set a $92.00 target price on shares of Medidata Solutions in a research report on Friday, October 27th. Finally, Wells Fargo & Company cut their target price on shares of Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating on the stock in a research report on Friday, October 27th. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $84.54.

Shares of Medidata Solutions (NASDAQ MDSO) traded up $0.76 during trading hours on Friday, reaching $66.23. 332,403 shares of the company’s stock were exchanged, compared to its average volume of 544,561. Medidata Solutions has a 12-month low of $47.77 and a 12-month high of $85.92. The company has a current ratio of 1.29, a quick ratio of 3.37 and a debt-to-equity ratio of 0.61. The company has a market cap of $3,775.41, a price-to-earnings ratio of 77.81, a P/E/G ratio of 4.02 and a beta of 1.69.

Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings data on Thursday, October 26th. The company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.02. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The firm had revenue of $140.08 million for the quarter, compared to analyst estimates of $141.27 million. During the same quarter in the prior year, the firm earned $0.28 EPS. The company’s revenue was up 16.7% on a year-over-year basis. analysts expect that Medidata Solutions will post 0.77 EPS for the current year.

In related news, Director Carlos Dominguez sold 9,066 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $66.85, for a total value of $606,062.10. Following the sale, the director now directly owns 66,020 shares in the company, valued at approximately $4,413,437. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Tarek Sherif sold 200,000 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $68.76, for a total transaction of $13,752,000.00. The disclosure for this sale can be found here. Insiders sold a total of 237,010 shares of company stock worth $16,305,136 over the last quarter. 5.80% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Fortaleza Asset Management Inc. acquired a new stake in shares of Medidata Solutions in the 3rd quarter valued at approximately $155,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Medidata Solutions by 10.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock valued at $171,000 after acquiring an additional 208 shares during the period. Polen Capital Management LLC acquired a new stake in shares of Medidata Solutions in the 3rd quarter valued at approximately $205,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Medidata Solutions in the 2nd quarter valued at approximately $227,000. Finally, ETF Managers Group LLC acquired a new stake in shares of Medidata Solutions in the 2nd quarter valued at approximately $233,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/08/medidata-solutions-mdso-coverage-initiated-by-analysts-at-deutsche-bank.html.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc and related companies with MarketBeat.com's FREE daily email newsletter.